Antimicrobial resistance (AMR) has emerged as one of the most consequential threats to global health, undermining decades of progress in the treatment of infectious diseases. Once reliably curable infections are increasingly difficult to manage, leading to prolonged illness, higher healthcare costs, and increased mortality (Sharma et al., 2026; Nazir et al., 2025). The drivers of AMR are multifactorial, encompassing the overuse and misuse of antibiotics in human medicine, agriculture, and aquaculture, alongside insufficient infection prevention measures and a stagnating pipeline of new antimicrobial agents (Ye et al., 2025). Addressing this complex challenge demands a coordinated and scientifically robust response, with pharmacology playing a central role in shaping innovative and sustainable solutions.

At its core, AMR is an evolutionary phenomenon. Microorganisms rapidly adapt to selective pressures imposed by antimicrobial agents, acquiring resistance through genetic mutations or horizontal gene transfer (Merker et al., 2020). The widespread and often indiscriminate use of antibiotics accelerates this process, enabling resistant strains to proliferate and disseminate. Consequently, traditional antimicrobial therapies are losing efficacy, particularly against high-priority pathogens such as multidrug-resistant Gram-negative bacteria (Muteeb et al., 2023). This reality underscores the urgency of developing novel pharmacological strategies that not only target resistant organisms but also minimize the emergence of further resistance.

One of the most promising avenues in combating AMR lies in the discovery and development of new antimicrobial agents with unique mechanisms of action. Advances in genomics, bioinformatics, and high-throughput screening have revitalized efforts to identify novel drug targets within microbial systems (Dakal et al., 2026; Lucero-Prisno et al., 2025). For instance, targeting bacterial virulence factors rather than essential survival pathways offers a strategy to disarm pathogens without exerting strong selective pressure for resistance. Similarly, antimicrobial peptides and synthetic mimetics are being explored for their broad-spectrum activity and reduced propensity for resistance development (Lu et al., 2025). These innovations reflect a paradigm shift from conventional bactericidal or bacteriostatic approaches toward more nuanced and sustainable therapeutic designs.

In parallel, drug repurposing has gained traction as a cost-effective and time-efficient strategy to address AMR. Existing drugs with established safety profiles are being re-evaluated for antimicrobial activity, either alone or in combination with traditional antibiotics (Aggarwal et al., 2024). This approach not only shortens the development timeline but also leverages existing pharmacokinetic and toxicological data. Notably, certain non-antibiotic drugs have demonstrated the ability to disrupt bacterial biofilms or enhance antibiotic uptake, thereby restoring the efficacy of previously ineffective treatments. Such combination therapies represent a pragmatic and immediately actionable pathway to mitigate resistance in clinical settings (Roque-Borda et al., 2026).

Another critical area of innovation is the optimization of drug delivery systems. Advanced delivery platforms, including nanocarriers, liposomes, and polymer-based systems, offer the potential to enhance drug concentration at infection sites while minimizing systemic exposure and toxicity (Eze et al., 2026; Uzakova et al., 2025). Targeted delivery not only improves therapeutic outcomes but also reduces the likelihood of subtherapeutic dosing, a known contributor to resistance development. For example, inhalable formulations for respiratory infections or localized delivery systems for wound infections can achieve high local drug concentrations, effectively eradicating pathogens while limiting off-target effects (Alidriss et al., 2025). These technologies exemplify how pharmaceutics and biopharmaceutics can contribute to the broader fight against AMR.

Pharmacokinetic and pharmacodynamic (PK/PD) optimization further strengthens antimicrobial therapy. Understanding the relationship between drug concentration, microbial killing, and resistance suppression is essential for designing effective dosing regimens (Alikhani et al., 2025). Advanced modeling and simulation techniques now allow for the prediction of optimal dosing strategies that maximize efficacy while minimizing resistance selection. Personalized dosing, informed by patient-specific factors such as age, organ function, and genetic variability, represents an extension of this approach. By tailoring therapy to individual patients, clinical pharmacology can significantly improve treatment outcomes and reduce the emergence of resistant strains (Marques et al., 2024; Minichmayr et al., 2024).

Beyond traditional antimicrobial agents, alternative therapeutic strategies are gaining increasing attention. Bacteriophage therapy, which utilizes viruses that specifically infect and lyse bacteria, offers a highly targeted approach to treating resistant infections (Olawade et al., 2024). Phage therapy can be tailored to individual patients and pathogens, providing a level of specificity that conventional antibiotics cannot achieve. Similarly, immunomodulatory therapies aim to enhance the host immune response, enabling the body to effectively combat infections without relying solely on antimicrobial drugs (Palma and Qi, 2024; Hibstu et al., 2022).

The human microbiome also represents a critical frontier in antimicrobial research. Disruption of the microbiome by broad-spectrum antibiotics can create ecological niches for resistant pathogens to thrive. Consequently, microbiome-preserving therapies and interventions, such as narrow-spectrum antibiotics or probiotic supplementation, are being explored to maintain microbial balance while treating infections (Patangia et al., 2022). Fecal microbiota transplantation has already demonstrated success in certain contexts, illustrating the therapeutic potential of microbiome-based approaches. Integrating microbiome considerations into pharmacological research may help mitigate unintended consequences of antimicrobial therapy (Ramesh et al., 2026; Uppala et al., 2026).

Despite these scientific advances, significant challenges remain in translating innovation into clinical practice. Economic barriers continue to hinder the development of new antibiotics, as the return on investment for antimicrobial drugs is often lower than for chronic disease therapies (Gargate et al., 2025). This has led to a decline in pharmaceutical industry engagement in antibiotic research and development. Addressing this issue requires novel economic models and policy interventions, including incentives for innovation, public-private partnerships, and global funding mechanisms. Regulatory frameworks must also evolve to accommodate the unique challenges associated with antimicrobial development, including the need for streamlined clinical trial designs and adaptive approval pathways (Gargate et al., 2025; Anderson et al., 2023).

Pharmacovigilance plays a crucial role in monitoring the safety and effectiveness of antimicrobial therapies post-approval. Robust surveillance systems are essential for detecting emerging resistance patterns and informing treatment guidelines (Khan et al., 2024). The integration of real-world data, electronic health records, and advanced analytics can enhance the detection of adverse drug reactions and resistance trends. Such data-driven approaches enable timely interventions and support evidence-based decision-making in both clinical and public health contexts (Mahadik et al., 2025).

Education and stewardship are equally vital components of the pharmacological response to AMR. Antimicrobial stewardship programs aim to optimize the use of antibiotics, ensuring that patients receive the right drug, at the right dose, for the right duration (El Bizri et al., 2026). These programs rely on interdisciplinary collaboration among clinicians, pharmacists, microbiologists, and public health professionals. Enhancing awareness among healthcare providers and the public about the risks of inappropriate antibiotic use is essential for sustaining the effectiveness of existing therapies. Pharmacology education must therefore emphasize not only drug mechanisms and efficacy but also responsible prescribing practices and resistance prevention strategies (Rodriguez et al., 2025).

Global collaboration is indispensable in addressing AMR, as resistant pathogens do not recognize national boundaries. International initiatives and partnerships are required to coordinate research efforts, share data, and implement effective interventions (Ashiru-Oredope et al., 2023). Low- and middle-income countries, which often bear a disproportionate burden of infectious diseases and have limited access to advanced therapeutics, must be actively included in these efforts. Strengthening healthcare infrastructure, improving access to diagnostics, and ensuring the availability of quality-assured medicines are critical steps toward a comprehensive global response (Eneh et al., 2026).

Combating antimicrobial resistance requires a multifaceted and forward-looking approach grounded in pharmacological innovation. From the discovery of novel antimicrobial agents and optimization of drug delivery systems to the integration of alternative therapies and data-driven pharmacovigilance, the field of pharmacology is uniquely positioned to lead this effort. However, scientific advances alone are insufficient without supportive economic, regulatory, and educational frameworks. By fostering collaboration across disciplines and sectors, and by prioritizing sustainability in drug development and use, the global community can address the challenge of AMR and safeguard the effectiveness of antimicrobial therapies for future generations.